Viloxazine
- TRADE NAME: Qelbree (Supernus)
- INDICATIONS: Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.
- CLASS: Norepinephrine reuptake inhibitor
- HALF-LIFE: ~7 hours
FDA APPROVAL DATE: 04/02/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Alfentanil, Alosetron, Atomoxetine, Avanafil, Clozapine, Conivaptan, CYP1A2 substrates, CYP2D6 substrates, CYP3A4 substrates, Darunavir, Desipramine, Dextromethorphan, Duloxetine, Everolimus, Ibrutinib, Isocarboxazid, Lomitapide, Lovastatin, Lurasidone, Metoprolol, Midazolam, monoamine oxidase inhibitors, Naloxegol, Nebivolol, Nisoldipine, Nortriptyline, Perphenazine, Phenelzine, Pirfenidone, Ramelteon, Rasagiline, Risperidone, Safinamide, Saquinavir, Selegiline, Simvastatin, Sirolimus, Tacrolimus, Tasimelteon, Theophylline, Tipranavir, Tizanidine, Tolterodine, Tranylcypromine, Triazolam, Vardenafil, Venlafaxine
May cause maternal harm; discontinue when pregnancy is recognized.
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
IN CLINICAL TRIALS, HIGHER RATES OF SUICIDAL THOUGHTS AND BEHAVIOR WERE REPORTED IN PEDIATRIC PATIENTS TREATED WITH VILOXAZINE THAN IN PATIENTS TREATED WITH PLACEBO. CLOSELY MONITOR FOR WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND BEHAVIORS.
See full prescribing information for complete boxed warning
Please login to see the rest of this drug profile
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
